- Stocks
- Pharma & Healthcare
- Ind-Swift Laboratories
Ind-Swift Laboratories share price
NSE: INDSWFTLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Ind-Swift Laboratories at a glance
Ind-Swift Laboratories (NSE: INDSWFTLAB) closed at ₹347.05 on 22 Oct 2026, up 1.92% on the day. With a market capitalisation of ₹3,018 Cr, it ranks 963rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 71.6× trailing earnings, against a return on equity of −70.5% in FY25. Over the past year the share price has risen 240.9%. Its 52-week range is ₹87.15 (31 Dec 2025) to ₹424.75 (30 Sep 2026); the last close is 18.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹170 Cr (+22.8% year on year) and net profit ₹15 Cr (−93.2%), on a consolidated basis. Promoters held 42.93% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹3,018 CrRank 963 on NSE
- P/E (trailing)
- 71.6×
- Price to book
- -0.17×FY25
- EPS (TTM)
- ₹5.26to Q4 FY26
- ROE
- −70.5%FY25
- ROCE
- 10.5%FY25
- Debt to equity
- -2.17FY25
- Net profit margin
- 55.0%FY25
- Book value / share
- −₹74.28FY25
- 52-week high
- ₹424.7530 Sep 2026
- 52-week low
- ₹87.1531 Dec 2025
- 1-year return
- +240.9%
- RSI (14-day)
- 42.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.92% | −5.9% | −9.2% | +49.0% | +240.9% |
Ind-Swift Laboratories quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹33 Cr | ₹12 Cr | ₹9 Cr | ₹138 Cr | ₹153 Cr | ₹153 Cr | ₹151 Cr | ₹170 Cr |
| Revenue YoY | −89.3% | −95.9% | −97.0% | −64.9% | +360.4% | +1,176.3% | +1,641.9% | +22.8% |
| Net profit | ₹1 Cr | ₹0 Cr | −₹0 Cr | ₹222 Cr | ₹9 Cr | ₹8 Cr | ₹10 Cr | ₹15 Cr |
| Net profit YoY | −94.2% | −98.7% | −100.1% | −6.9% | +756.4% | +1,910.0% | — | −93.2% |
| Net margin | 3.0% | 3.3% | −0.1% | 160.8% | 5.7% | 5.3% | 6.3% | 8.9% |
| EPS | ₹0.16 | ₹0.07 | — | ₹32.96 | ₹1.28 | ₹1.00 | ₹1.17 | ₹1.81 |
Ind-Swift Laboratories financials
| Item | FY17 | FY18 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹267 Cr | ₹271 Cr | ₹398 Cr | ₹411 Cr | ₹502 Cr | ₹515 Cr |
| Operating profit | −₹104 Cr | −₹25 Cr | −₹20 Cr | −₹35 Cr | ₹16 Cr | ₹8 Cr |
| Net profit | −₹364 Cr | −₹54 Cr | −₹20 Cr | ₹26 Cr | ₹14 Cr | ₹283 Cr |
| EPS (₹) | −₹69.00 | −₹9.00 | −₹4.00 | ₹5.00 | ₹3.00 | ₹52.00 |
| Cash from operations | −₹2 Cr | ₹7 Cr | ₹50 Cr | ₹73 Cr | ₹15 Cr | ₹16 Cr |
| Total debt | ₹665 Cr | ₹667 Cr | ₹619 Cr | ₹389 Cr | ₹995 Cr | ₹832 Cr |
| Shareholders' equity | −₹616 Cr | −₹663 Cr | −₹720 Cr | −₹691 Cr | −₹677 Cr | −₹402 Cr |
Ind-Swift Laboratories shareholding pattern
| Holder | 25 Aug 2025 | 30 Sep 2025 | 31 Dec 2025 | 24 Feb 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 39.50% | 39.50% | 39.50% | 43.06% | 42.99% | 42.93% |
| Foreign institutions | 14.91% | 14.80% | 14.33% | 13.80% | 13.88% | 10.70% |
| Domestic institutions | 0.68% | 0.68% | 0.68% | 0.16% | 0.00% | 0.17% |
| Non-institutions | 44.92% | 45.02% | 45.50% | 42.98% | 43.12% | 46.20% |
Ind-Swift Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Ind-Swift Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| UNICHEMLABUnichem Laboratories | ₹495.95 | −3.51% | +5.5% | ₹3,492 Cr | 13.8 | — |
| AARTIDRUGSAarti Drugs | ₹381.15 | −1.51% | −24.5% | ₹3,479 Cr | 17.9 | — |
| SOLARASolara Active Pharma Sciences | ₹650.75 | +1.48% | +11.8% | ₹3,140 Cr | — | — |
| INDSWFTLABInd-Swift Laboratories | ₹347.05 | +1.92% | +240.9% | ₹3,018 Cr | 71.6 | — |
| ADVENZYMESAdvanced Enzyme Technologies | ₹265.45 | +1.39% | −13.2% | ₹2,972 Cr | 17.6 | — |
| SHUKRAPHARShukra Pharma | ₹63.62 | −7.18% | — | ₹2,797 Cr | 127.2 | — |
| DPC02Dishman Pharma | — | — | — | ₹2,676 Cr | — | — |
Ask anything about Ind-Swift Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against INDSWFTLAB's own history. Try: “Why has INDSWFTLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on INDSWFTLAB over five years” · “Compare INDSWFTLAB with UNICHEMLAB on margins and valuation”
Frequently asked questions about Ind-Swift Laboratories
What is the share price of Ind-Swift Laboratories today?
Ind-Swift Laboratories (NSE: INDSWFTLAB) last closed at ₹347.05 on 22 Oct 2026. Its 52-week high is ₹424.75 and its 52-week low is ₹87.15.
What is the market cap of Ind-Swift Laboratories?
Ind-Swift Laboratories' market capitalisation is ₹3,018 Cr (₹3,018 Cr) at the 22 Oct 2026 close, ranking 963rd among the NSE companies Pivot tracks.
What is the P/E ratio of Ind-Swift Laboratories?
Ind-Swift Laboratories trades at a trailing P/E of 71.6. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 17.9.
What is the ROE and ROCE of Ind-Swift Laboratories?
Return on equity was −70.5% in FY25 and return on capital employed was 10.5% in FY25 (consolidated figures).
Is Ind-Swift Laboratories a debt-free company?
Ind-Swift Laboratories is close to debt-free: its debt-to-equity ratio was -2.17 in FY25.
What were Ind-Swift Laboratories' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Ind-Swift Laboratories reported revenue of ₹170 Cr, +22.8% year on year, and net profit of ₹15 Cr, −93.2% year on year.
How has Ind-Swift Laboratories stock performed over the last year?
Ind-Swift Laboratories' share price has risen 240.9% over the past year, +49.0% over three months and −9.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Ind-Swift Laboratories?
As of 30 Jun 2026: promoters 42.93%, foreign institutions 10.70%, domestic institutions 0.17%, non-institutions 46.20%.
Who are Ind-Swift Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Ind-Swift Laboratories by market cap are Unichem Laboratories, Aarti Drugs, Solara Active Pharma Sciences, Advanced Enzyme Technologies, Shukra Pharma and Dishman Pharma.
Is Ind-Swift Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Ind-Swift Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INDSWFTLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with I · all NSE stocks · this page as text